Acyclovir Expert Views

Dr. Jennifer Curtin discusses the use of antivirals, including Acyclovir, in treating conditions like ME/CFS and Long COVID. She explains that Acyclovir is not well absorbed orally, leading to the development of Valacyclovir, which is more commonly used. Studies from institutions like Stanford have shown that antivirals can lead to significant improvement in about half of ME/CFS patients. Dr. Curtin prefers Famciclovir over Valacyclovir due to lower risks of kidney issues, although these risks are rare and manageable with proper hydration. She also mentions that certain viruses, like CMV and HHV6, require different antivirals, as Acyclovir and its derivatives are ineffective against them.

Dr. Jennifer Curtin discusses the use of antivirals, including Valacyclovir (Valtrex), for treating Long COVID and ME/CFS. She explains that Valacyclovir is a commonly used antiviral due to its effectiveness in studies conducted by Stanford and other institutions. While Valacyclovir is generally safe, Dr. Curtin prefers Famciclovir for its better absorption and lower risk of kidney issues. She also mentions that certain viruses like CMV and HHV-6 require different antivirals, as Valacyclovir is not effective against them. Dr. Curtin highlights the importance of hydration to minimize potential kidney risks when using Valacyclovir.

Dr. Nancy Klimas, an expert in neuroimmunology, discussed the challenges of treating viral reactivations in conditions like Long Covid. She explained that while antivirals like valacyclovir are available, they are not highly effective. She mentioned that a more potent antiviral, valganciclovir, has shown promise in clinical trials for patients with high antibody levels indicating viral reactivation, but it is also more toxic. This highlights the complexity of treating viral reactivations, as different viruses require different treatments, and some treatments come with significant risks.

Dr. Nancy Klimas, an expert in neuroimmunology, discussed the use of antiviral treatments for Long Covid, particularly focusing on herpes family viruses like Epstein-Barr Virus (EBV) and Human Herpesvirus 6 (HHV6). She explained that while acyclovir is a common and accessible antiviral, it is not highly effective. More potent options like valganciclovir exist but come with significant toxicity and are typically reserved for severe cases. Klimas referenced a Stanford study by Dr. Montoya, which showed that patients with high antibody levels indicating EBV reactivation responded to valganciclovir. This highlights the importance of identifying viral reactivation through serology to guide treatment decisions.

The expert discusses the use of Acyclovir and similar antiviral drugs for treating Long Covid, emphasizing the importance of profiling a patient's herpes infections using IgG tests and PCR for specific viruses like HSV-6 and EBV. They note that some patients with chromosomally integrated herpes virus or chronic active EBV may benefit from these treatments. Acyclovir is often the first choice, but other drugs like Valganciclovir may be used depending on the patient's viral profile. The expert highlights that significant improvement is seen in some patients after prolonged antiviral treatment, lasting from one to five years.